Article Details

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of ... - Quantisnow

Retrieved on: 2024-12-08 04:42:21

Tags for this article:

Click the tags to see associated articles and topics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of ... - Quantisnow. View article details on hiswai:

Summary

The article discusses Beam Therapeutics' success in using BEAM-101 for sickle cell disease, highlighting its link to regenerative medicine. The treatment increased fetal hemoglobin levels, reduced sickle hemoglobin, and resolved anemia, demonstrating Beam's innovative approach in hemoglobinopathy treatment.

Article found on: quantisnow.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up